Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Revolution Medicines, Inc. (RVMD)

Revolution Medicines Q3 RASONQUE sales $197.6 million; net loss widens to $407.5 million

Mixed Impact 3 of 5 earnings Written later

Revolution Medicines reported third-quarter 2026 results, its first quarter with commercial sales of RASONQUE after FDA approval on August 26, 2026. Net product revenue was $197.6 million, but the net loss rose to $407.5 million from $305.2 million a year earlier, as research, development and selling costs increased. The company reiterated its full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, and it said the quarter's sales included early-launch effects and should not be read as a sign of the longer-term trend.

Key points

  • Net product revenue of $197.6 million for the quarter ended September 30, 2026, covering about five weeks after FDA approval, with the company citing initial stocking of product in the channel
  • Net loss of $407.5 million, or $1.90 per share, versus a net loss of $305.2 million, or $1.61 per share, a year earlier; the loss included $40.7 million of non-cash warrant fair value charges
  • Research and development expenses were $417.1 million and SG&A expenses were $153.3 million, compared with $262.5 million and $52.8 million a year earlier
  • Cash, cash equivalents and marketable securities were $3.7 billion at September 30, 2026, excluding $250 million received in October from the first Royalty Pharma debt tranche

The filing

CompanyRevolution Medicines, Inc. (RVMD)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:05 PM ET
Accession number0001193125-26-447193

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.